PMID- 22340047
OWN - NLM
STAT- MEDLINE
DCOM- 20121126
LR  - 20151119
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 33
IP  - 9
DP  - 2011 Sep
TI  - [HER-2 expression in advanced gastric cancer and its correlation with clinical 
      features, outcome and prognosis].
PG  - 671-5
AB  - OBJECTIVE: To assess the HER-2 status in Chinese advanced gastric cancer patients 
      and explore its correlation with clinical features, treatment response and 
      prognosis. METHODS: A total of 107 patients with advanced gastric cancer treated 
      in our hospital from December 2005 to November 2008 were included in this 
      retrospective analysis. HER-2 status was determined by immunohistochemisty (IHC) 
      and/or fluorescence in situ hybridization (FISH). The correlations of HER-2 
      status with tumor location, pathology, treatment response and prognosis were 
      analyzed and the efficacy of different chemottherapy regimens was compared. 
      RESULTS: The overall positive rate of HER-2 expression was 14.7% (15/102). The 
      HER-2 status was detected by both methods in 102 patients, and the concordance of 
      the two methods was 66.5%. The tumor site distribution was gastroesophageal 
      junction (GEJ) 28.0%, proximal stomach 19.4%, gastric corpus 16.1%, antrum 26.9% 
      and whole stomach 9.7%, respectively. There was no significant difference of 
      HER-2 status among different tumor sites (P = 0.726), and no significant 
      correlation between HER-2 expression and differentiation (P = 0.110). Among the 
      evaluable 51 patients treated by first-line chemotherapy, the total objective 
      effective rate was 23.5%. The median time-to-progression was 7.47 months, and 
      median overall survival time was 11.07 months. The effective rate was 43.8% in 
      patients who received XP regimen chemotherapy (cisplatin + capecitabine), 
      significantly higher than the 14.3% in patients treated with other regimens (P = 
      0.033). Their overall survival was 14.17 months and 9.53 months, respectively (P 
      = 0.059). The TTP was 6.63 months in HER-2 positive patients and 7.47 months in 
      HER-2 negative patients, with a non-significant difference (P = 0.510). However, 
      there was a improving tendency in the efficacy and OS, showing a effective rate 
      of 45.5% and 17.5% (P = 0.102) and OS of 14.17 months and 10.63 months, 
      respectively (P = 0.205). CONCLUSIONS: HER-2-positivity rate in Chinese patients 
      with advanced gastric cancer is similar to those reported in the literature. 
      Along with the increasing use of targeted therapy and targeted agents, the 
      efficacy and survival of gastric cancer patients is improving. HER-2-positive 
      patients may benefit from it.
FAU - Wang, Yan
AU  - Wang Y
AD  - Academy of Military Medical Sciences, Beijing, China.
FAU - Xu, Jian-ming
AU  - Xu JM
FAU - Liu, Jian-zhi
AU  - Liu JZ
FAU - Lin, Li
AU  - Lin L
FAU - Ge, Fei-jiao
AU  - Ge FJ
FAU - Li, Shan-shan
AU  - Li SS
FAU - Liu, Lie-jun
AU  - Liu LJ
FAU - Zhao, Chuan-hua
AU  - Zhao CH
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
RN  - 0W860991D6 (Deoxycytidine)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - Q20Q21Q62J (Cisplatin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - *Adenocarcinoma/drug therapy/metabolism/pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Capecitabine
MH  - Cisplatin/administration & dosage
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Disease Progression
MH  - Esophagogastric Junction/pathology
MH  - Female
MH  - Fluorouracil/administration & dosage/analogs & derivatives
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Receptor, ErbB-2/*metabolism
MH  - Retrospective Studies
MH  - Stomach/pathology
MH  - *Stomach Neoplasms/drug therapy/metabolism/pathology
MH  - Survival Rate
EDAT- 2012/02/22 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/02/21 06:00
PHST- 2012/02/21 06:00 [entrez]
PHST- 2012/02/22 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 2011 Sep;33(9):671-5.